Provider review
Sprout Health review: the FDA cited one sentence of its evidence copy, and it removed it
In September 2025 the FDA wrote to Sprout Health about one sentence on its website: "GLP-1 medications are FDA-approved and backed by extensive clinical research." The reply was a single line — compounded drugs are not FDA-approved, and saying so implies these products are the same as one that is. That is a claim-versus-evidence finding, made by the regulator, in exactly the form we make them. Sprout removed the sentence. We checked again this month and it is still gone. The letter is still open, because a corrected page does not close one.
The FDA objected to one sentence of its evidence copy; Sprout removed it, and now claims nothing about outcomes at all.
Worth trusting if
- You want both pharmacies and the clinical network named, which they are, with contact addresses
- You want a seller that states plainly that compounded medicines are not FDA-approved
- You want the brand-name product listed beside the compounded one, so you can see the real price gap
Be skeptical if
- You want published evidence from the seller, because it now offers none at all
- You treat an open warning letter as disqualifying — this one is open, and narrow
- You want to know whether your medication is made to order, which the terms do not say
Approved + compounded
Phase 3 trials
Named
September 2025
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens joinsprouthealth.com. A link is not a recommendation to take anything.
Provenance
What Sprout Health actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
The finished product holds an FDA approval and carries an NDC. Approval covers the specific product, dose form and indication on the label — not the molecule in general.
- Wegovy, brand — Listed from $1,799 a month — about twelve times the compounded semaglutide price.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection — Advertised from $149 a month; the sister site's checkout walk found a standing rate billed every four weeks.
- Compounded tirzepatide injection — Advertised from $199 a month.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
3
Molecules with human evidence
For the use they are sold for, out of 3 products reviewed here. The evidence belongs to the molecule, not to Sprout Health.
3
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Sprout Health’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim matches the trials
“Compounded Semaglutide. Real providers, real credentials — state-licensed medical providers, prescriptions filled by state-licensed pharmacies. Individual results vary and are not typical or guaranteed. Medications are prescribed only if clinically suitable.”
Read on the Sprout Health site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults, titrated to semaglutide 2.4 mg, mean weight reduction of about 15%. It tested the manufacturer's approved product — the distinction the FDA letter to this company turns on.
What Sprout says today is accurate, and it is accurate because a regulator told it to be. The site now attaches no weight-loss percentage, no pounds figure and no timeline to this product, and states plainly that compounded semaglutide and tirzepatide are not FDA-approved and have not been evaluated for safety, effectiveness or quality. That is the correct statement of the position. Read it beside what came before, though: the sentence FDA objected to said the opposite, and the reason the current copy is careful is an enforcement action rather than a change of heart. A company that now claims nothing has stopped overstating the evidence; it has not started demonstrating any.1
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim matches the trials
“Compounded Tirzepatide. Prescriptions, when clinically appropriate — if prescribed, most prescriptions are sent to the pharmacy within two business days of completing the required medical form.”
Read on the Sprout Health site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly, mean reduction of roughly 21% at the top dose. Again the manufacturer's approved product, not a compounded one.
Nothing on this product reaches past the trial, because nothing on it reaches at all. Sprout describes what tirzepatide is, how quickly a prescription reaches the pharmacy, and under what condition one is written, and makes no claim about the result. The hedge it does publish is the right one and is stated without qualification: individual results vary and are not typical or guaranteed.2
Wegovy, brandSemaglutide · FDA-approvedClaim matches the trials
“Wegovy® — Starting at $1799 month.”
Read on the Sprout Health site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. The trial that supported approval of this exact product. Unlike the compounded rows above, the evidence here attaches to the thing being sold.
This is the one product on the site where the trial evidence attaches directly to what is being sold. Wegovy is the manufacturer's approved semaglutide, and STEP 1 is the study behind its approval — so the ordinary caveat about compounded preparations does not apply. Sprout makes no efficacy claim for it beyond listing it, and the price it carries is roughly twelve times the compounded figure, which is the trade a buyer is actually being offered.1
Dispensing chain
Who actually fills your prescription
- Foothills Pharmacy
- Promise Pharmacy
Read the full account
Sprout names both pharmacies and its clinical network in its own terms, with a contact address for each — MD Integrations for the prescribing side, Foothills Pharmacy and Promise Pharmacy for dispensing. Re-read live on September 13, 2026. That is real disclosure and most of this market does not offer it. Two caveats. The compounding tier is not stated, so nothing tells you whether your medication is made to order under your prescription or dispensed ready-made. And the same clause misspells the company's own name as "Sprouth Health Partners LLC" — cosmetic, but it sits in the section a reader would use to check who they are dealing with.
Read on the Sprout Health site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published — and after the warning letter, very little else is either. Sprout's current pages carry no weight-loss percentage, no pounds figure, no timeline and no aggregate outcome of any kind, only member testimonials marked as not typical or guaranteed. That silence is the direct consequence of a regulator objecting to the one evidence sentence the site used to run, and it leaves a reader with nothing to check in either direction. The disclosure that does exist is about the supply chain rather than the product: two named pharmacies, a named clinical network, and a plain statement that compounded medicines are not FDA-approved.
Read on the Sprout Health site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Sprout publishes no list of states on its homepage or its terms, checked September 13, 2026. The sister site's August 2026 read found a contradiction worth carrying: the terms named 44 states and excluded California, where the company's own registered office is, while marketing elsewhere implied wider coverage. Confirm your own state before ordering rather than relying on either.
Read the full licensing claim
The operating company is named and addressed — Sprout Health Partners LLC, in Encinitas, California, with a published telephone number — and the clinical network is named as MD Integrations. No individual clinician, medical director or advisory panel is named.
Read on the Sprout Health site, September 2026.
Regulatory
The FDA warning letter
Issued September 2025
Sprout Health Partners LLC dba Sprout Health — 715879. Concerns marketing and labeling.
Read the full allegation
FDA reviewed joinsprouthealth.com in August 2025 and cited a single sentence of website copy: "GLP-1 medications are FDA-approved and backed by extensive clinical research…." Its objection is one line — "Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not" — which makes the products misbranded. The letter alleges nothing about sterility, potency, contamination or either pharmacy, and its only demand is that Sprout stop using that language. The subject line FDA files it under on its public index is considerably broader than the letter itself, which is why the text above quotes the body rather than the heading.
What has changed since
The cited sentence is gone. Every page on Sprout's site was checked on August 9, 2026 and none carried it, and we checked the homepage and terms again on September 13, 2026 with the same result. The pages now state the opposite — that compounded semaglutide and tirzepatide are not approved by the FDA and have not been evaluated for safety, effectiveness or quality. FDA has recorded no close-out, so the letter remains formally open. A warning letter is a public regulatory communication, not a finding of illegal activity.
Assessment
What holds up, and what does not
- It names both dispensing pharmacies and its clinical network, with a contact address for each.
- It states plainly that compounded semaglutide and tirzepatide are not FDA-approved or evaluated.
- The sentence the FDA objected to is gone, and stayed gone when we rechecked a year later.
Show 4 more
- It publishes its company name, a California address and a telephone number.
- Its testimonials are marked as not typical or guaranteed rather than presented as expectations.
- It lists the brand-name product beside the compounded one, at about twelve times the price.
- It says a prescription follows only if treatment is clinically suitable.
- It carries an open FDA warning letter, and no close-out has been recorded.
- That letter was about an evidence claim — telling readers GLP-1 medicines are FDA-approved.
- Its current pages make no outcome claim at all, so there is nothing to check in either direction.
Show 4 more
- No compounding tier is stated — nothing says whether your medication is made to order.
- No individual clinician is named; MD Integrations is a network rather than a person.
- Its own terms misspell the company as "Sprouth Health Partners LLC" in the contacts section.
- State coverage is unpublished, and an earlier read found its terms and its marketing disagreeing.
Verdict
The bottom line
Read the letter before you judge it, because the headline on the FDA index is far broader than what the letter actually says. It objects to one sentence of copy, demands that one sentence be removed, and alleges nothing about the medication or the pharmacies. Sprout removed it. What remains is a company that discloses its supply chain unusually well and now says nothing whatever about whether its product works.
Opens joinsprouthealth.com. A link is not a recommendation to take anything.
One sentence
On 9 September 2025 the FDA wrote to Sprout Health Partners LLC about joinsprouthealth.com. Here is the sentence it objected to:
"GLP-1 medications are FDA-approved and backed by extensive clinical research…."
And the reply, in full:
"Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not."
That is a claim-versus-evidence finding, made by a regulator, in exactly the form this site makes them. It is the reason Sprout is worth reading closely: almost every other letter in that enforcement wave cites marketing language in general terms, and this one cites a specific claim about what the evidence shows.
Full analysis — 4 more sectionsWhat the letter does not say · Sprout fixed it · What replaced it · Where it is genuinely good
What the letter does not say
It alleges nothing about sterility, potency, contamination, or either of Sprout's pharmacies. Its only demand is that the company stop using the language quoted above.
One caution if you are judging any company in this market by a warning letter: the heading the FDA files a letter under on its public index is often far broader than what the letter itself says. Open the letter.
Sprout fixed it
Every page on Sprout's site was checked in August 2026 and none carried the cited sentence. We checked the homepage and the terms again on 13 September 2026 and it is still absent.
The pages now say the opposite: that compounded semaglutide and tirzepatide are not approved by the FDA and have not been evaluated for safety, effectiveness or quality. That is the correct statement of the position.
The letter is still open. FDA has recorded no close-out, and a corrected page does not close one.
What replaced it
Nothing.
We swept the site on 13 September 2026 for a weight-loss percentage, a pounds figure, a timeline or any aggregate outcome. There is none. What remains is hedging — "Individual results vary and are not typical or guaranteed", "Medications are prescribed only if clinically suitable" — and member testimonials labeled as not typical.
That is compliance, and it is worth being precise about what it is not. A company that has stopped overstating the evidence has not started demonstrating any. The trials behind these molecules are strong 1 2, and Sprout now cites neither.
Where it is genuinely good
Its terms name the whole chain, with a contact address for each link: MD Integrations prescribing, Foothills Pharmacy and Promise Pharmacy dispensing. Most sellers in this market name a category and stop.
Two gaps remain. Nothing states whether your medication is made to order under your prescription or dispensed ready-made. And the same clause misspells the company's own name as "Sprouth Health Partners LLC" — cosmetic, but it sits in the section you would use to check who you are dealing with.
Questions
Frequently asked questions
What was Sprout's FDA warning letter about?
One sentence on its website claiming GLP-1 medications are FDA-approved and backed by extensive clinical research. The FDA's objection was that compounded drugs are not FDA-approved and saying so implies these products are equivalent to one that is. The letter alleges nothing about sterility, potency or either pharmacy.
Has that been fixed?
Yes. The sentence was gone when every page was checked in August 2026, and still gone when we rechecked the homepage and terms in September. The pages now state plainly that compounded semaglutide and tirzepatide are not FDA-approved or evaluated.
Is the letter closed?
No. FDA has recorded no close-out, so it remains formally open even though the copy was corrected. A warning letter is a public regulatory communication rather than a finding of illegal activity, and fixing the page does not close the file.
What does Sprout claim its treatment achieves?
Nothing measurable, which is a direct consequence of the letter. There is no weight-loss percentage, pounds figure or timeline anywhere on the site — only testimonials marked as not typical or guaranteed. It has stopped overstating the evidence without starting to show any.
Which pharmacy fills the prescription?
Foothills Pharmacy or Promise Pharmacy, both named in Sprout's own terms with contact addresses, alongside MD Integrations on the prescribing side. What the terms do not say is whether your medication is made to order for you or dispensed ready-made.
Why is Wegovy so much more expensive?
Because it is the manufacturer's approved product rather than a compounded preparation. Sprout lists it at $1,799 a month against $149 for compounded semaglutide — roughly twelve times. The trial evidence attaches directly to Wegovy; for the compounded version it describes the molecule rather than the preparation.
Glossary
Key terms
Show definitions
- Warning letter
- A public notice from the FDA telling a company it believes something is violating the law, and asking it to correct it. It is a communication rather than a finding of illegal activity, and it stays open until the FDA records a close-out.
- Misbranded
- In US drug law, labeled or advertised in a way that is false or misleading. The objection to Sprout's sentence was that it implied a compounded product was equivalent to an approved one.
- Compounded
- Made to order by a pharmacy for an individual patient rather than manufactured and approved as a finished product. Compounded drugs are not FDA-approved and the FDA has not evaluated their safety, effectiveness or quality.
Compare
Others selling what Sprout Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Sprout Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults over 68 weeks, the trial behind the approval of branded semaglutide for weight management. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults over 72 weeks at 5, 10 and 15 mg once weekly. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.